Provided are a drug-loaded implantable medical instrument and a manufacturing method therefor. The drug-loaded implantable medical instrument (10) comprises an instrument body (100), a microporous membrane (200) fixed on the instrument body (100), and a nanocrystal medicament (300) loaded on the microporous membrane (200). A method for preparing a drug-loaded implantable medical device includes: providing a microporous membrane; loading a nanocrystalline drug on the microporous membrane; and fixing the microporous membrane loaded with the nanocrystalline drug to the device body.

Aggregates formed from one or both of chitosan and hyaluronan, suspended or otherwise dispersed in a liquid carrier are useful for treating joint or muscle distress in a subject, where the composition may include one or more pharmaceutically active agents and the composition in locally delivered to the joint or muscle by, for example, injection.

A drug-loaded implanted medical device (10) and a preparation method therefor. The drug-loaded implanted medical device (10) comprises a device body (100), a hydrophilic coating layer (200) loaded on the device body (100), and crystalline drug particles (300) loaded on the hydrophilic coating layer (200). The hydrophilic coating layer (200) comprises a graft polymer containing a photo-crosslinked group. The medical device (10) uses a hydrophilic coating layer (200) as a carrier, effectively avoiding the risk of embolism, encouraging the crystalline drug particles to fall off, and helping to achieve a target tissue concentration. The invention can also effectively increase the anchoring effect between the carrier and the device, and reduce toxicity.

A balloon catheter is disclosed that can effectively deliver a drug to living body tissue, a method of manufacturing a balloon catheter, and a treatment method. A balloon catheter is disclosed, the balloon catheter is provided on an outer surface of a balloon with a plurality of elongate bodies which are independent crystals of a water-insoluble drug extending in an elongate form. The elongate bodies include fixed-side elongate bodies which are fixed to the outer surface side of the balloon, and top-side elongate bodies which are bent or broken from the fixed-side elongate bodies and are continuous with or independent of the fixed-side elongate bodies.

The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a drug coating layer that primarily uses therapeutic agents alone for improving the quality of treatments in which drug coated balloons are utilized. Particular aspects may be directed to drug coated balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes at least one therapeutic agent and is substantially free of excipients.

A biocompatible implant according to one aspect of the present disclosure includes a base and a calcium phosphate coating film located on a surface of the base and including silver. The calcium phosphate coating film includes a plurality of calcium phosphate particles located on a surface thereof, and a plurality of needle-like crystals located on a surface of the plurality of calcium phosphate and the plurality of needle-like crystals are located in a gap at an interface between adjacent calcium phosphate particles among the plurality of calcium phosphate particles.

A drug coating layer that prevents breakage of elongated drug crystals on a balloon surface while maintaining the drug crystals in an appropriate shape to act on the living body includes plural elongated bodies which are crystals of a water-insoluble drug each extending from the surface of the balloon at various lengths and angles, and a water-soluble additive layer provided in a space between an outer surface of an aggregate of the elongated bodies and the balloon surface to fill a space between the elongated bodies. The outer surface of the additive layer being located outside the aggregate, being uneven connecting a plurality of tip ends and side surfaces of the elongated bodies to each other. The tip ends of the elongated bodies slightly protrude from the additive layer, and the side surfaces and/or tip surfaces of the elongated body are exposed on the surface of the additive layer.

A drug-releasing polymer composition is disclosed. It may include a major component, which may be ethylene vinyl acetate, and may further include at least one or two release-modifying materials, and may further include at least one or two drugs. The release-modifying materials may be polyethylene glycol and polycaprolactone. The drugs may be minocycline and rifampin. There may be an interaction such that in the presence of two different release-modifying materials, drug release may be greater than with either release-modifying material alone. There may be an interaction such that in the presence of two drugs, drug release may be greater than with either drug alone, and antibacterial performance may be enhanced. Release durations as long as two months are possible. In addition, the composition can be provided on a medical device that is configured for implanting in body tissue for an extended time period.

The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a microcrystalline structure and techniques for increasing vascular permeability for drug application and retention. Particular aspects may be directed to a medical device including a balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes microcrystals in a haystack orientation having random and a substantial absence of uniformity in placement and/or angle on the outer surface of the balloon.

Provided herein is a coated coronary stent, comprising: a. stent framework; b. a plurality of layers deposited on said stent framework to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.